Previous Page  34 / 62 Next Page
Information
Show Menu
Previous Page 34 / 62 Next Page
Page Background

C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl

32

Neumol Pediatr 2016; 11 (1): 28 - 32

10. Chevaillier, J. Autogenic drainage: An airway clearance

technique. Unpublished abstracts 2000, 21st European

Cystic Fibrosis Conference (EWGCF), Davos, Switzerland.

11. Bradley JM, Moran FM, Elborn JS. Evidence for physical

therapies (airway clearance and physical training) in cystic

fibrosis: an overview of five Cochrane systematic reviews.

Respir Med 2006;100:191-201

12. Darbee JC, Ohtake PJ, Grant BJ, Cerny FJ. Physiological

evidence for the efficay of positive expiratory pressure

as an airway clearance technique in patients with cystic

fibrosis. Phys Ther 2004;84:524-37

13. Oberwaldner B, Evans JC, Zach MS. Forced expirations

against a variable resistance: a new chest physiotherapy

method in cystic fibrosis. Pediatr Pulmonol 1986;2:358-67

14. Oberwaldner B, Theissl B, Rucker A, Zach MS. Chest

physiotherapy in hospitalized patients with cystic fibrosis:

a study of lung function effects and sputum production. Eur

Respir J 1991; 4:152-58

15. Pfleger A, Theissl B, Oberwaldner B, Zach MS. Self-

administered chest physiotherapy in cystic fibrosis: a

comparative study of high-pressure PEP and autogenic

drainage. Lung 1992; 170:323-30

16. Zach MS, Oberwaldner B. Effect of positive expiratory

pressure breathing in patients with cystic fibrosis. Thorax

1992; 47:66-67

17. Brooks D, Newbold E, Kozar LF, Rivera M. The flutter device

and expiratory pressures. J Cardiopulm Rehabil 2002 ;

22:53-7

18. Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation

of the acute efficacy, acceptability and tolerability of flutter

and active cycle of breathing with and without postural

drainage in non cystic fibrosis bronchiectasis. Chron Respir

Dis 2007;4:23-30

19. Decramer M, Gosselink R. Physical activity in patients with

cystic fibrosis: a new variable in the health-status equation

unravelled? Eur Respir J 2006:678-9

20. Dennersten U, Lannefors L, Höglund P, Hellberg K, Johansson

H, Lagerkvist A-L, Ortfelt M, Sahlberg M, Eriksson L. Lung

function in the aging Swedish cystic fibrosis population.

Respir Med 2009;

21. Dolovich MB, Fink JB. Aerosols and devices. Respir Care

Clin N Am 2001; 7: 131-173

22. Dolovich MA. Influence of inspiratory flow rate, particle

size, and airway caliber on aerosolized drug delivery to the

lung. Respir Care 2000 ; 45: 597-608